| Objective:To investigate the relation of serum testosterone(T)with the incidence and risk stratification of prostate cancer(PCa).Methods:A total of 81 patients who underwent prostate biopsy in Beijing Hospital from 2007 to 2018 were retrospectively studied.All patients were biopsy naive and met the criteria for prostate biopsy.Serum T level were detected before biopsy.Baseline characteristics,serum PSA,T level and gleason scores were collected for further analysis.Patients were divided into two groups according to the diagnosis of benign prostatic hyperplasia(BPH)and PCa(defined as BPH group and PCa group,respectively later).Patients in PCa group were then subdivided by risk stratification using gleason score and serum PSA level,respectively.Data among these groups were compared.Results:No statistical differences were found in serum T level between BPH group and PCa group(P=0.989).The ROC analysis showed no diagnostic significance for PCa with Serum T level(P=0.970).Subgroup analysis with gleason score showed significant differences in serum T level(P=0.038).The serum T level between Gleason score?6 group and Gleason score?8 group was significantly different(P=0.044).No significant differences were found in serum T level among serum PSA subgroups(P=0.641).Conclusion:Serum T level has no value for the diagnosis of PCa.However,there is a correlation between high serum T level and high-risk prostate cancer.Objective:To explore the effect of maximum androgen blockade(MAB)therapy on metabolic indicators in patients with prostate cancer(PCa).Methods:The clinical data of 273 PCa patients treated with MAB from January 2010 to December 2018 in Beijing Hospital were retrospectively studied.All patients diagnosed pathologically by prostate biopsy.Ages,medical history,treatment plan and metabolic indicators for serum lipid,glucose,calcium and phosphorus before and after hormonal therapy were collected.Among all the patients,complete data were collected in 118 cases for serum lipid indicators,196 cases for glucose indicators and 156 for serum calcium and phosphorus.Subgroup analysis of indicators for serum lipid,glucose,calcium and phosphorus before and after therapy was conducted according to patients'age,history of hyperlipodemia and diabetes mellitus(DM),respectively.Results:As for lipid metabolism,the total cholesterol(TC),triglycerides(TG)and low density lipoprotein cholesterol(LDL-C)were significantly higher after MAB therapy(P=0.002,0.001,0.001,respectively)while no significant difference was found in high density lipoprotein cholesterol(HDL-C)(P=0.880).The subgroup analysis showed no statistical difference in TC,TG,HDL-C and LDL-C in patients with hyperlipidemia(P=0.087,0.050,0.212,0.303,respectively)while TC,TG and LDL-C were significantly higher(P=0.005,0.003,0.002,respectively)except HDL-C(P=0.790)in patients without hyperlipidemia.As for glucose metabolism,fasting blood glucose(FBG)was significantly higher after MAB therapy(P<0.001).The subgroup analysis showed,no significant difference in FBG in patients with DM(P=0.321)but a significant elevation in patients without DM(P<0.001).As for calcium-phosphorus metabolism,there was a significant difference in serum phosphorus and calcium-phosphorus ratio(P=0.001,0.041,respetively)but none in serum calcium(P=0.107).The subgroup analysis showed no significant differences in serum calcium,serum phosphorus and calcium-phosphorus ratio in patients younger than 65 years(P=0.427,0.403,0.756,respectively)while serum phosphorus and calcium-phosphorus ratio saw a significant elevation(P=0.001,0.028,respectively)but serum calcium(P=0.164)in patients older than 65 years.Conclusion:MAB therapy can affect serum lipid and glucose level in PCa patients,as well as the calcium-phosphorus metabolism of elderly PCa patients.For patients who received MAB therapy,the above indicators should be closely monitored and attention should be paid to preventing the occurrence of related complications. |
PDF Full Text Request